Trial Search Results
A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis
The purpose of this study is to evaluate the safety and tolerability of orally administered TG101348 in patients with myelofibrosis.
Stanford is currently not accepting patients for this trial.
- Drug: TG101348
- Diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential
- At least 18 years of age.
- ECOG PS 0, 1, or 2.
- Any chemotherapy, immunomodulatory therapy, immunosuppressive therapy,
corticosteroids, or growth factor treatment within 14 days prior to initiation of
- Major surgery or radiation therapy within 28 days prior to initiation of study drug.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study